Tobira Therapeutics (TBRA) Posts Q2 Loss of $0.71/Share; Ended Qtr with $41M in Cash
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Tobira Therapeutics Reports Second Quarter 2016 Financial and Business Results
August 9, 2016 4:01 PM EDT-Guest Speaker Arun Sanyal, M.D. to Speak on CENTAUR Study and NASH Landscape-
-Conference Call to be Held Today at 4:30 p.m. Eastern Time-
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ: TBRA) a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today reported business highlights and financial results for the three months ended June 30, 2016.
We are excited about the results of the CENTAUR trial, which we believe is the first study to... More
